Case ReportSingle Centre Experience with GORE-HELEX Septal Occluder for Closure of PFO
Introduction
There are several approved devices for percutaneous patent foramen ovale (PFO) closure.1, 2 Since November 2003, our planned treatment strategy of PFO closure has been routine use of the GORE-HELEX septal occluder device (GORE, Flagstaff, AZ, USA), followed by 6 months of aspirin therapy. The use of this device has been reported to be more difficult and associated with a greater learning curve compared with other currently available devices.3 The GORE-HELEX device has a sheathless delivery system and an intrinsic retrieval system. In our experience the low-profile nature favours a more axial alignment with the septum and conforms to the length of the PFO tunnel. We present the safety and feasibility of using this device for all adult patients undergoing percutaneous PFO closure, with 3-month transthoracic echocardiogram (TTE) follow up.
Section snippets
Methods
This study was a single centre, retrospective cohort study of all patients referred for percutaneous PFO closure at the John Radcliffe Hospital in Oxford between 1st January 2004 and 31st December 2006. Patients were identified from the cardiac catheterisation laboratory database, and the medical records of all patients were reviewed. All devices were deployed by one of three operators under transoesophageal (TOE), transthoracic (TTE) or intracardiac echocardiography (ICE) guidance. During the
Results
In total, 75 adult patients were referred for PFO closure during the study period. There were 34 males (45.3%), and the mean age of patients was 44.0 ± 11.7 years. Referral indications were stroke or TIA (n = 53), peripheral embolism (n = 9), decompression sickness (n = 9) and severe migraine (n = 4).
All patients had ultrasound guided PFO closure, with ICE in 64, TOE in 10 and TTE in one patient. Atrial septal aneurysms were present in 16/75 (21.3%). At the time of procedural echocardiography, no PFO was
Discussion
To our knowledge this is the largest published single centre experience of adult PFO closure with the GORE-HELEX septal occluder. Our study demonstrates that a planned treatment strategy of PFO closure with routine use of the GORE-HELEX septal occluder device for all patients is safe, feasible and associated with a high rate of procedural success.
The structure of the HELEX occluder is designed to conform to the contours of the septum without bulky protrusion into the atria. It is composed of a
References (5)
- et al.
Patent foramen ovale with paradoxical embolism: mid-term results of transcatheter closure in 256 patients
J Interv Cardiol
(2003) - et al.
Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems
Eur Heart J
(2004)
Cited by (11)
PFO Closure for Cryptogenic Stroke
2015, Current Atherosclerosis ReportsPercutaneous removal of unraveled HELEX® septal occluder 4 months post deployment
2015, Catheterization and Cardiovascular InterventionsComparison of residual shunt rates in five devices used to treat patent foramen ovale
2014, Catheterization and Cardiovascular InterventionsShort and long term complications of device closure of atrial septal defect and patent foramen ovale: Meta-analysis of 28,142 patients from 203 studies
2013, Catheterization and Cardiovascular InterventionsInitial use of the new GORE® septal occluder in patent foramen ovale closure: Implantation and preliminary results
2013, Catheterization and Cardiovascular Interventions